Clinical Trials Logo
  1. Home
  2. Solid Tumor, Unspecified, Adult
  3. NCT03628677

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Solid Tumor, Unspecified, Adult Clinical Trial

Official title:
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Clinical Trial Summary

This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in combination with zimberelimab (AB122) in participants with advanced solid malignancies.

Clinical Trial Description

This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab as monotherapy and in combination with zimberelimab in participants with advanced solid malignancies. In this dose escalation study, participants will receive domvanalimab administered intravenously as monotherapy or in combination with zimberelimab. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for study drug discontinuation occurs. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03628677
Study type Interventional
Source Arcus Biosciences, Inc.
Contact
Status Active, not recruiting
Phase Phase 1
Start date September 12, 2018
Completion date November 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05723640 - The Safety and Dosimetry Study of 177Lu-LNC1004 Injection Phase 1
Completed NCT04976803 - Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
Recruiting NCT04932525 - Gustave Roussy Cancer Profiling Phase 1
Recruiting NCT04643418 - Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04443088 - An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04942717 - Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
Recruiting NCT04169321 - Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors Phase 1
Recruiting NCT05695638 - Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
Completed NCT03318445 - Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Phase 1
Recruiting NCT04537936 - Psychotherapy Intervention for Latinos With Adv Cancer N/A
Completed NCT04252339 - RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT04577963 - A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06136065 - 68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors Phase 2
Recruiting NCT04015609 - Psychotherapy Intervention for Latinos With Advanced Cancer N/A
Available NCT04100694 - Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor